Therapy in Huntington's disease: where are we? (Q38006434)

26 August 2017

title

Therapy in Huntington's disease: where are we? (English)

1 reference

26 August 2017

0 references

Martha A Nance

1 reference

26 August 2017

publication date

1 August 2012

1 reference

Current Neurology and Neuroscience Reports

26 August 2017

published in

1 reference

26 August 2017

1 reference

26 August 2017

1 reference

26 August 2017

page(s)

359-366

1 reference

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

21 January 2018

Benign hereditary chorea

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Neurocognitive signs in prodromal Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Longitudinal change in regional brain volumes in prodromal Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Assessment of depression, anxiety and apathy in prodromal and early huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Assessment of cognitive symptoms in prodromal and early huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Assessment of motor symptoms and functional impact in prodromal and early huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Assessment of Day-to-Day Functioning in Prodromal and Early Huntington Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Pharmacological management of Huntington's disease: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Suicidal behavior in prodromal Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Suicidal ideation in Huntington disease: the role of comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Comorbidities of obsessive and compulsive symptoms in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Treatment of Apathy in Huntington’s Disease and Other Movement Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Effect of donepezil on motor and cognitive function in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Two years' follow-up of rivastigmine treatment in Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Longitudinal Change in Gait and Motor Function in Pre-manifest Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Falls and gait disturbances in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Fall risk assessment using the Tinetti mobility test in individuals with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Deficits in stepping response time are associated with impairments in balance and mobility in people with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Adherence to Use of a Home-Based Exercise DVD in People With Huntington Disease: Participants' Perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Effects of an intensive rehabilitation programme on patients with Huntington's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Coordinated multidisciplinary care for Huntington's disease. An outpatient department

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Coordinated multidisciplinary care for ambulatory Huntington's disease patients. Evaluation of 18 months of implementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Gardening with Huntington's disease clients--creating a programme of winter activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Characteristics of individuals with Huntington disease in long-term care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Dysphagia in Huntington’s Disease: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Harris-Benedict equation estimations of energy needs as compared to measured 24-h energy expenditure by indirect calorimetry in people with early to mid-stage Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Assessment of the nutrition status of patients with Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Use of oral nutritional supplements in patients with Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Perspectives of staff providing care at the end of life for people with progressive long-term neurological conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Promoting Excellence in End-of-Life Care: lessons learned from a cohort of nursing home residents with advanced Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Huntington's disease: a caring approach to the end of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Palliative care provision in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Exploring supportive care for individuals affected by Huntington disease and their family caregivers in a community setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Huntington's disease. Part 3: family aspects of HD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Living with Huntington's disease: need for supportive care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Predictive testing for Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Healthcare experiences of families affected by Huntington disease: need for improved care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Huntington disease: families' experiences of healthcare services

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0277-4

Therapeutic interventions for disease progression in Huntington's disease

21 January 2018

1 reference

12 December 2020

Preimplantation genetic diagnosis (PGD) for Huntington's disease: the experience of three European centres

1 reference

12 December 2020

Unified Huntington's disease rating scale: Reliability and consistency

1 reference

12 December 2020

Therapeutic interventions for symptomatic treatment in Huntington's disease

1 reference

12 December 2020

Huntington's Chorea, Leukemia at end-of-life, G-tubes, open access to hospice

1 reference

12 December 2020

Ripples from a stone skipping across the lake: a narrative approach to the meaning of Huntington's disease.

1 reference

12 December 2020

Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate alleles).

1 reference

12 December 2020

10.1007/S11910-012-0277-4

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1024122582

0 references

1 reference